Clinical study data
Latest News
Probe successful with EU grant
Probe Scientific has been successful in its application for grant funds as part of the highly rated EU clamp study. This will result in Probe’s MicroEye® being evaluated in a number of key European centres. MicroEye® will be evaluated with a variety of different sensor and pump systems
Despite increasing expenditure on diabetes treatment, many suffers do not achieve good glycaemic control. New drugs are in development and a key technology in their search is the euglycaemic glucose clamp technique. This method measures the effectiveness of a new anti-diabetic drug to lower blood glucose levels by stabilising a subject’s blood glucose concentration at a target level through a variable infusion of glucose. Our EU-CLAMP Project aims to develop a new generation of automated clamp device using Probe’s MicroEye platform technology. The EU-CLAMP project receives funding from the European Union’s Seventh Framework Programme.
Further information is available from the at EU-Clamp Project website at http://www.euclamp.eu
Clinical Data
Probe Scientific has been working closely with two leading companies in Germany, focussed on clinical research involving diabetes and glucose monitoring. Following ethics approval a Clinical Study has been conducted and results from this confirm that Probe's MicroEye® device with an online sensor system is, in the opinion of the users, a world-beating combination in terms of its usability, reliability and performance.
The current gold standard for blood glucose monitoring involves the withdrawal of a blood sample followed by offline Point of Care measurement. This typically involves a skilled healthcare professional using a blood line (which must be flushed regularly to stop it clotting); to withdraw blood at timed intervals. The blood must then be prepared before it is run on a bench-top analyser.
Disadvantages of the current Gold Standard Method:
- The skilled healthcare professional must be available at the necessary times (which could be as frequent as every 10 minutes)
- The blood line must be kept open so a sample can be taken
- The blood must be prepared for analysis
- Blood not used is wasted
- Wasted blood and blood stained materials must be disposed of, which is costly
- The presence of blood increases the risk of infection.
Probe's MicroEye® device has been developed to overcome these problems:
- The system provides useable data within minutes of deployment
- Blood is not withdrawn and is not wasted
- The sample does not need to be prepared
- It can be measured online in a continuous manner using biosensors
- As this is automated the skilled healthcare professional need only oversee the process when convenient in a timely and efficient manner.
Latest clinical studies
Probe successful with EU grant
Probe has been successful in its application for grant funds as part of the highly rated EU clamp study. This will result in Probe’s MicroEye® being evaluated in a number of key European centres with a variety of different sensor and pump systems.
Glucose monitoring during OGTT
Recent studies confirm MicroEye® is excellent compared to an approved reference method.
Interested in using the MicroEye® for your research?
We can supply the MicroEye® for use in your research or clinical trials. If you would like more information on purchasing please complete our contact form.